Daiichi Sankyo Company, Limited
Securities code: 4568 · Sector: Pharma
Daiichi Sankyo researches, develops, manufactures and sells pharmaceutical products in Japan and overseas.
Annual figures
Amounts in ¥ million
Scroll right for earlier years
| Figure | FY ended Mar 2026 Filed 2026-06-19 | FY ended Mar 2025 Filed 2025-06-20 | FY ended Mar 2024 Filed 2024-06-17 |
|---|---|---|---|
| Revenue | 2,123,045 | 1,886,256 | 1,601,688 |
| Operating income | 229,089 | 331,925 | 211,588 |
| Profit attributable to owners of the parent | 259,874 | 295,756 | 200,731 |
| Total assets | 4,005,390 | 3,456,119 | 3,461,135 |
| Equity attributable to owners of the parent | 1,664,179 | 1,623,416 | 1,688,173 |
Notes
- Figures as filed in each year's annual securities report, not restated. Check the original filing on EDINET.
- Equity is the equity attributable to owners of the parent (自己資本), which excludes non-controlling interests.
Source and attribution
Includes EDINET Taxonomy content, excluded from PDL 1.0 and separately licensed (EDINET Taxonomy legal statement). © Copyright 2014 Financial Services Agency, The Japanese Government.
Kabuken is not a financial instruments business operator under the Financial Instruments and Exchange Act and does not provide investment advice.
Companies in the same sector
More annual report figures
Look up any listed company in the Kabuken app or ask an AI assistant through the Kabuken MCP server. Open Kabuken